Distal Femur Tümör Rezeksiyon Protezlerinde Sağkalım ve Sağkalımı Etkileyen Faktörlerin Değerlendirilmesi
Ambargo SüresiAcik erisim
Üst veriTüm öğe kaydını göster
With improvements in chemoterapy drugs and modalities, implant production and implementation, innovations in surgical techniques and correct patient selection; amputation lost his place as first line surgical treatment to limb salvage surgery for over 30 years. Endoprostehtic reconstruction become the preffered choice of surgeons in limb salvage surgery. In our study we included 54 patient (29 woman, 25 man) who had distal femur tumor resection prosthesis between 2001-2020 at Hacettepe University Orthopedics and Traumatology Department and we studied prosthesis survival, evaluation of complications, patient survival and functional assessment. Patients who had distal femur endoprosthesis for nontumor conditions excluded from this study. MSTS scoring system used for functional assessment. Minimum follow up was 1 year and survival analysis are made with Kaplan-Meier analysis. 54 patienst included 27 (%50) osteosarcoma, 9 (%16.7) metastasis, 7 (%13) Ewing sarcoma. 11(%20.4) grouped as others included 4 giant cell tumor patients, 3 chondrosarcoma, 2 multiple myeloma, 1 synovial sarcoma and 1 lymphoma. According to age groups ;28 adult (%51.9) and 26 pediatric (%48.1) patienst involved. By the time of last examinations; 38 patients (%70.4) was alive. We found similar prosthesis survival, patient survival and complication rates with current literature and our patient group. When interpreted with the functional assesments; tumor resection prosthesis found to be safe and successful method of treatment for lower limb tumor and reconstruction.